ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,047 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 26-50 of 1,000 matching filings.

Per page
25
Current page
2
6-K File 001-11960

ADMISSION OF FURTHER SECURITIES TO TRADING

Filing date
03 Aug 2026
Reporting date
03 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Aug 2026
Reporting date
03 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATROWAY APPROVED IN EU FOR TNBC

Filing date
31 Jul 2026
Reporting date
31 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA

Filing date
27 Jul 2026
Reporting date
27 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS

Filing date
27 Jul 2026
Reporting date
27 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER

Filing date
23 Jul 2026
Reporting date
23 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR

Filing date
14 Jul 2026
Reporting date
14 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL

Filing date
09 Jul 2026
Reporting date
09 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
08 Jul 2026
Reporting date
06 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ADMISSION OF FURTHER SECURITIES TO TRADING

Filing date
01 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS

Filing date
29 Jun 2026
Reporting date
29 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC

Filing date
29 Jun 2026
Reporting date
29 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
16 Jun 2026
Reporting date
08 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TRUQAP APPROVED IN US FOR PROSTATE CANCER

Filing date
15 Jun 2026
Reporting date
15 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ADMISSION OF FURTHER SECURITIES TO TRADING

Filing date
01 Jun 2026
Reporting date
01 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jun 2026
Reporting date
01 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER

Filing date
29 May 2026
Reporting date
29 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-11960

25-NSE filing

Filing date
28 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

US FDA DECISION DATE ON CAMIZESTRANT EXTENDED

Filing date
27 May 2026
Reporting date
27 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC

Filing date
26 May 2026
Reporting date
26 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS

Filing date
26 May 2026
Reporting date
26 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU

Filing date
26 May 2026
Reporting date
26 May 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .